Chris Viehbacher appointed Sanofi-Aventis CEO

Share this article:
Chris Viehbacher
Chris Viehbacher
Sanofi-Aventis announced September 10 that Chris Viehbacher will succeed Gerard Le Fur as the company's CEO, effective December 1, 2008. 

The announcement came two days after Viehbacher resigned his postion on GlaxoSmithKline's board, with plans to leave the company entirely. Viehbacher will remain executive director and president at GSK until December 1.

Viehbacher, also a PhRMA board member, was a contender for the CEO position at GSK following the retirement of Jean-Pierre Garnier last May. Andrew Witty, currently the CEO at GSK, secured that postion.

According to a statement from the Sanofi board of directors, Le Fur will stay on at Sanofi after Viehbacher becomes CEO, and will "provide his competences to the general management of the group in the scientific domain." The financial conditions of Viehbacher's hiring will be posted online in the coming days, according to the Sanofi statement. 
Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.